Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How would you choose between Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation.
Related Questions
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?
Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?
Do you recommend pharmacological ADT for a patient with hypogonadism with unfavorable or high risk prostate cancer whose testosterone was castrate (<20) without supplementation?
How does the presence of PSMA negative lesions in a patient with mCRPC affect your decision to treat with Lutetium (177Lu) vipivotide tetraxetan?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?
